Cytotoxicity of Melatonin and Derivatives on Human Liver Cell Lines

Article Sidebar

PDF (ภาษาไทย)
Published: Apr 30, 2023
Keywords:
Melatonin Melatonin derivatives Cytotoxicity Chang liver cell line HepG2 cell lines

Main Article Content

Sawan Thitisutthi
Division of Environmental Health, Faculty of Public Health, Mahasarakham University
Karnjana Sae-Ung
Division of Occupational Health and Safety, Faculty of Liberal Arts and Sciences, Sisaket Rajabhat University
Wipa Chuppawa
Division of Occupational Health and Safety, Faculty of Liberal Arts and Sciences, Sisaket Rajabhat University

Abstract

Melatonin (MT) is a hormone synthesized and secreted by the pineal gland that has been shown to directly induce cell death as well as exhibit oncostatic activity. However, its short biological half-life and the lack of selectivity of melatonin at the target sites limit its potential as an anticancer agent. This study aimed to develop a new class of anticancer agents by N-substituting the indole ring of melatonin and testing its derivatives on human liver (Chang) and human liver carcinoma (HepG2) cell lines for their cytotoxicity using MTT assay. The percent yield of N-methyl melatonin, Acetate melatonin, Benzoyl melatonin, and Napthoyl melatonin derivatives were 43.41%, 44.78%, 54.55% and 30.50%, respectively. Interestingly, melatonin showed no cytotoxicity on both Chang liver and HepG2 cell lines after 24h exposure, while all its derivatives showed cytotoxicity on both cell lines at varying levels. Therefore, these findings provide promising insight for the development of melatonin derivatives as effective anticancer agent, which can be further improved for its selectivity in future study

Article Details

How to Cite
Thitisutthi , S., Sae-Ung, K., & Chuppawa, W. (2023). Cytotoxicity of Melatonin and Derivatives on Human Liver Cell Lines. Journal of SciTech-ASEAN, 3(1), 45–53. retrieved from https://li01.tci-thaijo.org/index.php/STJS/article/view/256980
Issue
Vol. 3 No. 1 (2023): January - June 2023
Section
Research Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The content and information in the articles published in the Journal of Science and Technology, Sisaket Rajabhat University reflect the opinions and responsibilities of the respective authors. The editorial board of the journal does not necessarily agree with, nor share responsibility for, these views.

Articles, information, content, images, etc., published in the Journal of Science and Technology, Sisaket Rajabhat University are copyrighted by the Faculty of Science and Technology, Sisaket Rajabhat University. If any individual or organization wishes to republish all or part of the content, or use it for any other purpose, they must obtain written permission from the Journal of Science and Technology, Sisaket Rajabhat University beforehand.

References

World Health Organization (WHO). (2022). Cancer. Retrieved 10 September 2022, from https://www.who.int/news-room/fact-sheets/detail/cancer.

Ferlay. J., Colombet, M., Soerjomataram, I., Parkin, DM., Piñeros, M., Znaor, A. and Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of cancer, 149(5), 778-789.

Tan, XW., Xia, H., Xu, JH. and Cao, JG. (2009). Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gen-difluoromethylenechrysin. World Journal of Gastroenterology, 15(18), 2234-2239.

Menéndez-Menéndez, J. & Martínez-Campa, C. (2018). Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers. International Journal of Endocrinology, 2018(1), 1-20.

Martin-Renedo, J., Mauriz, JL. and Jorquera, F. (2008). Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. Journal of Pineal Research, 45(4), 532–540.

Blask, DE., Sauer, LA. and Dauchy, RT. (2002). Melatonin as a chronobiotic/anti-cancer agent: cellular biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Current Topics in Medicinal Chemistry, 2(2), 113–132.

Joo, SS. & Yoo, YM. (2009). Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. Journal of Pineal Research, 47(1), 8–14.

Marot, C., Chavatte, P., Morin-Allory, L., Viaud, M.C., Guillaumet, G., Renard, P., Lesieur, D. and Michel, A. (1998). Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors. Journal of Medicinal Chemistry, 41(23), 4453-4465.

Rivara, S., Pala, D., Bedini, A. and Spadoni, G. (2015). Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014). Expert Opinion on Therapeutic Patents, 25(4), 425-441.

Blask, DE., Sauer, LA., Dauchy, RT., Holowachuk, EW., Ruhoff, MS. and Kopff, HS. (1999). Melatonin Inhibition of Cancer Growth in Vivo Involves Suppression of Tumor Fatty Acid Metabolism via Melatonin Receptor-mediated Signal Transduction Events. Cancer research, 59(15), 4693–4701.

Sauer, LA., Dauchy, RT. and Blask, DE. (2001). Polyunsaturated fatty acids, melatonin and cancer prevention. Biochemical Pharmacology, 61(12), 1455–1462.

Lissoni, P. (2002). Is there a role for melatonin in supportive care?. Supportive Cancer Care, 10(2), 110–116.

Zhou, J., Lei, W., Shen, L., Luo, HS., and Shen, ZX. (2008). Primary study of leptin and human hepatocellular carcinoma. World Journal of Gastroenterology, 14(18), 2900-2904.

Rodriguez-Garcia, A., Hevia, D., Mayo, JC., et al. (2017). Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells. Redox Biology, 12(1), 634–647.

Wang, Z., Fan, J., Liu, M., et al. (2013). Nutraceuticals for prostate cancer chemoprevention: From molecular mechanisms to clinical application. Expert Opinion on Investigational Drugs, 22(1), 1613–1626.

Fan, LL., Sun, GP., Wei, W., Wang, Z.-G., Ge, L., Fu, W.-Z. and Wang, H. (2010). Melatonin and Doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World Journal of Gastroenterology, 16(12), 1473-1481.